
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated a positive financial outlook, as evidenced by a projected acceleration in procedure volumes exceeding 50% year-over-year in the second half of 2026, driven by commercial initiatives. The company reported strong capital system placements, achieving 58 new systems, surpassing prior guidance, which signals robust demand despite a slightly softening macroeconomic environment. Additionally, Q3'25 financial results indicate sales of $83.3 million, reflecting a 43% year-over-year increase and exceeding both internal targets and consensus estimates, further highlighting the company's growth trajectory and strong market positioning.
Bears say
The financial outlook for PROCEPT BioRobotics is largely negative due to several concerning metrics reported in its recent financial disclosures. The company reported fourth quarter revenue that was 19% below consensus expectations and subsequently lowered its fiscal year 2026 sales guidance by 5%, resulting in a midpoint estimate that is significantly below analyst projections. Furthermore, the decline in handpiece sales, attributed to the elimination of bulk purchase discounts and inventory de-stocking, indicates operational challenges that may hinder future revenue growth.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares